This present study indicates that there is a sub-population of prostate cancer patients that express erbB-2 and have its pathway activated; such patients could possibly benefit from current anti-erbB2 therapies, such as Herceptin, currently in use in breast cancer. Here, ERBB2 is linked to breast carcinoma.